Technical Analysis for BLCM - Bellicum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 4.29 -4.45% -0.20
BLCM closed down 4.45 percent on Friday, November 16, 2018, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical BLCM trend table...

Date Alert Name Type % Chg
Nov 16 Fell Below 20 DMA Bearish 0.00%
Nov 16 180 Bearish Setup Bearish Swing Setup 0.00%
Nov 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Nov 16 Outside Day Range Expansion 0.00%
Nov 15 Crossed Above 20 DMA Bullish -4.45%
Nov 15 Up 3 Days in a Row Strength -4.45%
Nov 14 Pocket Pivot Bullish Swing Setup -1.83%
Nov 14 Wide Bands Range Expansion -1.83%
Nov 13 NR7 Range Contraction 1.90%
Nov 13 NR7-2 Range Contraction 1.90%

Older signals for BLCM ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of various forms of cancer. Its lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Its preclinical product candidates include BPX-401, a chimeric antigen receptor (CAR-T) product candidate for the treatment of hematological cancers that express the CD19 antigen; BPX-601, a CAR-T product candidate for treating solid tumors overexpressing the prostate stem cell antigen; and BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Is BLCM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 10.4
52 Week Low 3.92
Average Volume 373,757
200-Day Moving Average 6.8352
50-Day Moving Average 5.3252
20-Day Moving Average 4.385
10-Day Moving Average 4.427
Average True Range 0.3212
ADX 25.65
+DI 19.3513
-DI 22.6725
Chandelier Exit (Long, 3 ATRs ) 4.6164
Chandelier Exit (Short, 3 ATRs ) 4.8836
Upper Bollinger Band 4.9407
Lower Bollinger Band 3.8293
Percent B (%b) 0.41
BandWidth 25.345496
MACD Line -0.2743
MACD Signal Line -0.3327
MACD Histogram 0.0584
Fundamentals Value
Market Cap 142.54 Million
Num Shares 33.2 Million
EPS -2.94
Price-to-Earnings (P/E) Ratio -1.46
Price-to-Sales 975.18
Price-to-Book 2.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.86
Resistance 3 (R3) 4.90 4.76 4.77
Resistance 2 (R2) 4.76 4.61 4.74 4.73
Resistance 1 (R1) 4.52 4.52 4.45 4.48 4.70
Pivot Point 4.38 4.38 4.34 4.36 4.38
Support 1 (S1) 4.14 4.23 4.07 4.10 3.88
Support 2 (S2) 4.00 4.14 3.98 3.85
Support 3 (S3) 3.76 4.00 3.82
Support 4 (S4) 3.72